瑞银：上调京东健康目标价至45港元

Core Viewpoint - UBS believes JD Health is enhancing user experience and expanding market share through increased reinvestment [1] Revenue Growth Projections - JD Health's revenue compound annual growth rate (CAGR) is expected to be 15% from 2024 to 2026, surpassing peers [1] - UBS has raised JD Health's revenue forecasts for 2025-2027 based on accelerated online drug penetration and market share expansion [1] Target Price and Rating - The target price for JD Health has been increased from HKD 35.2 to HKD 45, with a rating of "Buy" [1]